# OnCo record keynote-010 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-010/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-010", "NCT01905657" ;
  schema:name "KEYNOTE-010"@en ;
  schema:description "The trial that validated PD-L1 staining as a way of choosing who gets immunotherapy, and gave pembrolizumab its first lung cancer approval."@en ;
  schema:url <https://onco.cc/trials/keynote-010/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT01905657>, <https://doi.org/10.1016/S0140-6736(15)01281-7>, <https://www.nice.org.uk/guidance/ta428> ;
  onco:status "positive" ;
  onco:phase "2/3" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/pdl1-high-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/companion-diagnostic/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/docetaxel/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/immune-checkpoint/> ;
  onco:trials <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/checkmate-017/>, <https://onco.cc/trials/oak/> .